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Abstract
Subclinical inflammation is a risk factor for cardiovascular disease. The mechanisms underlying increased levels of inflammatory markers
and their changes in response to weight loss are not fully understood yet. It has been proposed that elevated concentrations of C-reactive
protein (CRP) are mediated by cytokines produced in adipose tissue. We investigated the changes in circulating CRP after weight reduction,
in relation to parameters relevant to the metabolic syndrome. Forty 25- to 35-year-old obese female volunteers participated in an intervention
program of dietary education and supervised physical activity for a period of 9 weeks. Anthropological parameters and biochemical
measurements (high-sensitivity CRP [hsCRP], plasma lipoproteins, interleukin 6 [IL-6], adiponectin) were analyzed before and after the
intervention. Body mass index decreased by more than 7% from 31.5 F 4.1 to 29.1 F 3.9. Plasma free fatty acid (FFA) concentrations
decreased by 30%, high-density lipoprotein cholesterol increased by 8%, and fasting insulin concentrations decreased by 15%. There were no
significant changes in either low-density lipoprotein cholesterol or triacylglycerol concentrations. Subcutaneous and visceral adipose tissue
mass decreased by 12% and 18%. High-sensitivity CRP concentrations decreased by 30%; however, mean plasma IL-6 and adiponectin
concentrations remained unchanged. In linear regression analysis, the changes in plasma hsCRP concentrations were associated with baseline
hsCRP concentration, change in triacylglycerols and FFA concentrations, and in waist circumference. The decrease in hsCRP concentration
after weight reduction does not appear to be mediated by decreases in circulating IL-6 or adiponectin concentrations; however, change in
hsCRP concentration is related to changes in waist circumference and lipid metabolism, reflected by plasma triacylglycerol and FFA levels.
D 2006 Elsevier Inc. All rights reserved.1. Introduction
Lipoprotein abnormalities, hypertension, and insulin
resistance (associated with the metabolic syndrome) are
important and highly prevalent risk factors for the develop-
ment of premature coronary heart disease [1]. However,
there is mounting evidence implicating a heightened0026-0495/$ – see front matter D 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.metabol.2005.09.010
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(A. Dvorˇa´kova´-Lorenzova´).immune response and inflammation in the initiation and
progression of the atherosclerotic disease, as has been
suggested by Ross [2]. Moderate increases in circulating
levels of C-reactive protein (CRP) within nonpathological
breference Q range, detected with high-sensitivity methods
(high-sensitivity CRP [hsCRP]), have been documented to
be a sensitive marker of subclinical inflammation (ie,
proinflammatory state) [3]. During the last few years,
several studies have associated moderate elevation of this
immediate-phase protein with an increased risk of coronary
heart disease [4,5]. Elevated hsCRP concentrations are
associated with obesity [6], insulin resistance [6,7], andxperimental 55 (2006) 359–365
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[9-14]. In addition, hsCRP appears to be a sensitive
indicator of endothelial dysfunction (now widely recognized
as an early event in atherogenesis) and is also correlated
with urinary albumin excretion, suggesting a link to renal
vascular pathology [14].
It has been proposed that atherosclerosis and type 2
diabetes mellitus probably share a common inflammatory
basis, as suggested by known relationship between param-
eters related to insulin resistance and hsCRP concentrations
[15]. Cytokines produced by monocytes and macrophages
in the subendothelium of atherosclerotic lesions or by
adipocytes are believed to stimulate hsCRP production.
Recent evidence suggests that obesity per se can directly
affect the progression of coronary atherosclerosis in young
men [16], supporting again an inflammatory basis for
atherosclerosis progression observed in obesity. It has been
proposed that immediate-phase reactants, predominantly
characterized by interleukin-6 (IL-6), promote hsCRP
production by the liver as a component of the subclinical
inflammation related to obesity.
In the present study, we examined changes in the
proinflammatory status of young obese women, assessed
by circulating concentrations of hsCRP, in relation to the
lipoprotein concentrations, insulin resistance, circulating
IL-6 and adiponectin concentrations, and anthropometric
parameters (including adipose tissue volume) after a
lifestyle intervention consisting of dietary education and
exercise intervention intended to achieve weight reduction.2. Research design and methods
2.1. Subjects and study protocol
A group of 40 young obese female volunteers recruited
via an advertisement on a lifestyle web site and in women’s
journal underwent a 9-week course of lifestyle intervention.
The inclusion criteria were 25 to 35 years of age and
body mass index (BMI) of more than 29 kg/m2. Exclusion
criteria were known inflammatory or metabolic diseases
(diabetes, thyroid gland disease, any other endocrine
disorders, autoimmune diseases, any chronic inflammation,
or neoplastic disease). The intervention consisted of dietary
education (comprising a weekly supervised dietary record)
combined with increase in physical activity. Dietary
education was aimed at lowering energy intake, together
with decrease in animal fat intake. Eating more fruits
and vegetables was also encouraged. The volunteers
participated 3 times weekly in a supervised 1-hour training
session at a fitness center, and 3 more sessions per week of
cycling, jogging, or brisk walking. All these activities
included an aerobic exercise component—the participants
were supervised (and advised) to sustain heart rate of 130 to
135 beats per minute for 45 minutes within 60 minutes of
exercise. The details of intervention have been published
elsewhere [17].The women received a physical examination at baseline
and after the intervention. The subjects completed ques-
tionnaires assessing health and lifestyle activities. Measure-
ments included height, weight, waist, hips, body
composition (magnetic resonance imaging [MRI] scan for
subcutaneous and visceral fat volume), heart rate, blood
pressure, and collection of blood samples for determination
of lipoprotein, free fatty acid (FFA), insulin, glucose,
hsCRP, IL-6, and adiponectin concentrations. Before en-
rolling in the study, written consent was obtained from each
subject. The informed consent form and the study protocol
were approved by the Ethics Committee of the Institute for
Clinical and Experimental Medicine.
2.2. Assays, MRI, and data analysis
Plasma triacylglycerol levels, and total, high-density
lipoprotein cholesterol (HDL-C), and low-density lipoprotein
cholesterol (LDL-C) concentrations were measured enzy-
matically by a standardized procedure (Centers for Disease
Control and Prevention external quality control system),
using Cobas Mira analyzer (Hoffman-LaRoche). High-
sensitivity CRP concentration was measured by an ultrasen-
sitive assay from Orion-Diagnostica. Very low-density
lipoprotein cholesterol (VLDL-C) and VLDL-triacylglycerol
concentrations were measured after ultracentrifugation at
the separated fraction of VLDL. Free fatty acid concen-
trations were analyzed by colorimetric method [18]. The
measurement of IL-6 concentration was performed with an
immunoradiometric assay (IRMA) assay from Biosource
(California; distributed by Eurorad Ltd, Praha, Czech
Republic). The insulin concentrations were determined
using an IRMA assay of Immunotech (Prague, Czech
Republic). Adiponectin was measured in samples available
from 27 subjects with a radioimmunoassay for human
adiponectin (Linco Research, St Charles, MO).
Measurements of visceral and subcutaneous fat volumes
were obtained from 28 of the 40 subjects enrolled in the
study by an MRI, using Siemens (Germany) Vision 1.5-T
scanner. Twenty-one continuous axial slices covered the
section of abdomen 10 cm above and below the umbilicus.
Segmentation of the fat volume was performed using our
homebuilt software application written in PV-WAVE (Visual
Numerics). An automatic procedure for finding the thresh-
old of the fat signal using a histogram evaluation of the
complete volume was developed, and the volume of fat
tissue was calculated after manual delineating of the fat
volume by 2 independent observers [19].
Statistical analyses were performed using R statistical
software (www.r-project.org). Pairwise associations be-
tween the target variables were assessed using the Pearson
correlation coefficient. Multiple linear regression was used
to explain observed pairwise differences in hsCRP concen-
trations (postintervention minus baseline values or
DhsCRP). Simple regression models may not reveal existing
associations between the predictors and the response
variable because of confounding, as was the case in this
Table 1
Characteristics of the women at the baseline and after intervention (mean F SD)
N = 40 Baseline After intervention P %D
Weight (kg) 88.56 F 12.51 81.75 F 11.95 b .001 7.7 F 2.4
BMI (kg/m2) 31.52 F 4.08 29.09 F 3.89 b .001 7.7 F 2.4
Waist circumference (cm) 93.2 F 10.3 85.5 F 9.1 b .001 8.2 F 3.6
Hip circumference (cm) 114.3 F 8.0 106.3 F 8.8 b .001 7.0 F 3.2
Waist-hip ratio 0.82 F 0.06 0.80 F 0.06 .163 1.2 F 5.2
Systolic blood pressure (mm Hg) 127.6 F 9.0 119.7 F 9.9 b .001 6.4 F 6.9
Diastolic blood pressure (mm Hg) 81.0 F 7.4 76.7 F 7.7 .001 4.9 F 9.5
Heart rate (beats per min) 81 F 8 79 F 7 .143 1.7 F 8.7
Subcutaneous fat (cm3) (n = 28) 706 F 164 624 F 170 b .001 12.3 F 9.2
Visceral fat (cm3) (n = 28) 1667 F 801 1375 F 6860 b .001 18.5 F 11.5
Visceral-subcutaneous ratio 2.35 F 0.18 2.18 F 0.17 b .001 7.1 F 8.5
Total cholesterol (mmol/L) 5.26 F 0.82 5.31 F 0.85 .595 1.6 F 11.6
Triacylglycerols (mmol/L) 1.20 F 0.50 1.24 F 0.50 .516 11.4 F 43.0
LDL-C (mmol/L) 3.06 F 0.71 3.01 F 0.74 .462 1.1 F 14.1
HDL-C (mmol/L) 1.53 F 0.34 1.62 F 0.39 b .05 7.8 F 21.7
FFA (mmol/L) (n = 39) 0.86 F 0.31 0.57 F 0.19 b .001 30.9 F 31.7
VLDL-triacylglycerols (mmol/L) (n = 33) 0.610 F 0.456 0.609 F 0.431 .982 9.0 F 75.6
VLDL-C (mmol/L) (n = 33) 0.264 F 0.175 0.278 F 0.168 .718 5.3 F 71.6
Glucose (mmol/L) 5.21 F 0.43 5.32 F 0.34 .094 2.5 F 7.7
Insulin (lIU/mL) 10.1 F 4.9 8.6 F 4.2 b .01 6.8 F 41.6
HOMA index 2.33 F 1.13 2.04 F 1.01 .090 3.0 F 46.9
hsCRP (mg/L) 4.31 F 3.71 3.01 F 3.12 .0002 30.1 F 39.1
IL-6 (pg/L) (n = 33) 9.01 F 6.47 11.25 F 7.21 .249 35.0 F 81.4
Adiponectin (lg/mL) (n = 27) 7.9 F 2.6 7.5 F 2.9 .64 3.6 F 19.3
The statistical significance is based on the paired t test. WHR indicates waist-hip ratio.
A. Dvorˇa´kova´-Lorenzova´ et al. / Metabolism Clinical and Experimental 55 (2006) 359–365 361analysis. The effects of covariates such as the change in FFA
concentration, the change in waist circumference, or the
change in triacylglycerol values were in this analysis
confounded by the effect of the strongest predictor, the
initial values of hsCRP. When adjusted for the effect of
initial values of hsCRP on the observed differences in
hsCRP, an independent effect of other covariates may be
properly assessed. The associations indicated by the
multiple regression model could not have been identified
using simple regression model (or correlations). Thus, a
major issue in this analysis was the need to adjust for the
effect of initial hsCRP concentrations.
To further test the validity of the results of our linear
regression analysis, additional analyses were performed to
exclude possible bias caused by outlier values. In the first
additional analysis, all women with an increase in hsCRP
concentration (n = 3) were excluded, and in the second
analysis, all women with extreme hsCRP were dropped
(n = 3). Finally, both of these extremes were excluded.
Nevertheless, the results of the linear regression analysis as
shown in Table 2 were stable in all these additional analyses,
without any change in the trends.3. Results
3.1. Body composition and blood pressure
Mean weight loss during the intervention period was
6.8F 0.4 kg (range, 2.6-12.0 kg) for approximately 7.7% F
0.4% (range, 3.1% to 12.1%) of baseline body weight
(Table 1). Waist circumference decreased by 8% and hipcircumference by 7%, but the waist-hip ratio was unaltered
during the intervention. Subcutaneous abdominal fat volume
decreased by 12% and visceral fat volume by 18%. The
ratio of visceral to subcutaneous fat decreased by ~7% after
the intervention period (Table 1). Visceral fat volume at
baseline was positively correlated with BMI (r = 0.58,
P = .0013), waist-hip ratio (r = 0.54, P = .0028), and
hsCRP (r = 0.39, P = .043), and inversely with HDL levels
(r = 0.54, P = .003). The decrease in waist circumference
correlated with the change in visceral fat volume (r = 0.57,
P b .005), but not with the change in subcutaneous
fat volume (r = 0.11, P = .60). Detailed results of
the changes in body composition have been published
previously [17].
Significant decreases in both systolic and diastolic blood
pressures were noted. No change in resting heart rate was
observed during the study. There was no significant
correlation between the changes in blood pressure and
decreases in body weight.
3.2. Lipids, glucose, and insulin
Measurements obtained at the baseline and after the
intervention are presented in Table 1. Serum concentrations
of total and LDL-C were within reference ranges at baseline
and did not change significantly after the intervention. High-
density lipoprotein cholesterol increased significantly, and
plasma FFA concentrations decreased by 30% from 0.86 F
0.31 to 0.57 F 0.19 mmol/L (P b .0001). There was no
significant change in triacylglycerol concentration. Fasting
insulin concentrations at baseline were positively correlated
Fig. 1. High-sensitivity CRP concentration at the baseline and after
intervention (individual changes shown as black lines).
Table 2
Analysis of variance for hsCRP difference (final  baseline values)
Parameter df Mean square P (NF)
Baseline hsCRP 1 42.63 b .0001
Waist difference 1 7.854 .0026
FFA difference 1 7.205 .0037
Triacylglycerol difference 1 18.376 b .0001
Baseline hsCRP * waist difference 1 14.021 .0001
Residuals 30 0.726 –
Mean squares indicate the proportion of (total or explained) variance
corresponding to each predictor in the linear regression model.
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plasma insulin levels decreased from 10.08F 4.85 to 8.57F
4.19 lU/mL (P = .02), suggesting increased insulin
sensitivity. However, fasting plasma glucose levels, which
were within reference range at baseline, did not change
during the intervention period, and the decrease in the
homeostasis model assessment (HOMA) index of insulin
resistance was not statistically significant.
3.3. High-sensitivity CRP, IL-6, and adiponectin
A 30% reduction in plasma hsCRP concentrations was
one of the most prominent outcomes of the lifestyle
intervention (Fig. 1), decreasing from 4.31 F 3.71 to
3.01 F 3.12 mg/L (double P = .0002). The medians were
3.35 (interquartile range, 1.47/5.17) at the baseline and 1.46
(interquartile range, 0.7/3.99) after intervention. The median
of hsCRP change was 0.86 (interquartile range, 2.33/
0.13). A decrease in hsCRP concentration was observed in
all but 4 women (Fig. 1). Mild infection was documented in
2 of these 4 subjects afterward. In contrast, plasma IL-6
concentrations did not change during the intervention
period: baseline, 9.01 F 6.47; after intervention, 11.25 F
7.21 pg/L (P = .249) (Fig. 2). Adiponectin levels did not
increase after the intervention.Fig. 2. Interleukin 6 concentration at the baseline and after intervention
(individual changes shown as black lines).3.4. Correlations
Baseline hsCRP concentrations were positively correlat-
ed with baseline BMI (r = 0.36, P = .02), visceral (r = 0.51,
P = .0059) and subcutaneous (r = 0.42, P = .028) fat
volumes, and waist circumference (r = 0.44, P = .0046).
High-sensitivity CRP concentration after intervention was
correlated with final BMI (r = 0.42, P = .0064), waist
circumference (r = 0.41, P = .0091), triacylglycerol
concentration (r = 0.37, P = P = .019), visceral (r = 0.50,
P = .0069) and subcutaneous (r = 0.497, P = .0072) fat
volumes, hip circumference (r = 0.37, P = .019), fasting
insulin (r = 0.36, P = .021), and HOMA index (r = 0.35,
P = .029). Other correlations for baseline and final hsCRP
concentration or its change were not statistically significant.
Visceral fat mass at baseline was inversely related to plasma
HDL levels (r = 0.54, P = .003).
At baseline, plasma adiponectin concentrations were
negatively correlated with BMI (r = 0.42, P = .025) and
highly positively correlated with HDL levels (r = 0.65,
P = .0002). High-sensitivity CRP tended to be inversely
related to adiponectin levels (r = 0.36, P = .065). As
discussed, adiponectin did not increase during the interven-
tion, and changes in adiponectin were not related to the
changes in BMI, HDL, or hsCRP levels.
The following variables were included in the linear
regression analysis: all the parameters shown in Table 1,
except for visceral and subcutaneous fat volumes and
adiponectin levels (because the measurements were avail-
able only for 28 of our 40 subjects), plus scored physical
activity and adherence to diet. The changes in hsCRP
concentrations were significantly correlated with 5 param-
eters: hsCRP at baseline (P b .001), the change in waist
circumference (P = .0026), the change in FFA concen-
trations (P = .0037), the change in triacylglycerol levels
(P b .001), and combined parameter of baseline hsCRP
concentrations and waist difference (P b .001). According
to the estimates of influence, a 1 mmol/L reduction in
triacylglycerol concentration resulted in an average reduc-
tion in hsCRP concentration of 1.53 mg/L.
According to the mean squares in analysis of variance
(Table 2), 47.3% of the total explained variability in the
changes in hsCRP during the intervention was attributed to
baseline concentrations of hsCRP. Another 20.4% was
mediated by change in triacylglycerol concentration,
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trations mediated additional 8.7% and 8.0% of the hsCRP
concentration differences, respectively. An interactive term
of baseline hsCRP and the change in waist circumference
mediated the remaining 15.6% of the total explained
variability in hsCRP change. This multiplicative term
expresses the fact that the magnitude of hsCRP reduction
may be different with the same decrease in waist circum-
ference, depending on the baseline hsCRP. The total
variability left unexplained by the model, as described by
the corresponding mean square, was only 0.726 on 30 df.4. Discussion
A substantial decrease in weight and body adiposity was
achieved in women during the 9-week intervention by a
combination of dietary changes and increased physical
activity. Because the women in the present study were well
aware of the composition of a healthy diet before entering
the study, only minor dietary changes were made to reach an
optimal dietary composition in most subjects. However,
restriction of energy intake was emphasized because
average energy intake of the subjects before the study was
estimated to be approximately 25% higher than the
recommended daily allowance according to the age and
physical activity. Most previous studies, examining the
effects of weight loss on proinflammatory status in obese
individuals, used dietary intervention only (or other means
to decrease energy intake, eg, gastric banding).
As would be expected, the amount of the body weight
lost depended on the adherence to the dietary regimen and
physical activity program—these results have been previ-
ously published elsewhere [17]. The duration of our study
was shorter than in other studies, but with more intensive
regimen, documented by a highly significant decrease in
body weight of 6.8 kg in 9 weeks, compared with weight
loss of 14 kg within 2 years in the study by Esposito and
colleagues [12].
Average baseline total cholesterol, LDL-C, and triacyl-
glycerol concentrations were already within reference
ranges, and minor dietary changes did not result in a further
lowering. A highly significant 30% reduction of plasma FFA
levels was observed, likely induced by increased physical
activity [20]. Increase in HDL-C concentration can also be
ascribed to the increase in physical activity, a result similar to
that reported by Rennie et al [21], in whose study a relatively
short (9 weeks) exercise intervention was sufficient to
produce statistically significant increase in HDL-C.
Fasting plasma insulin concentrations decreased signif-
icantly. Increases in insulin sensitivity after weight reduction
have been documented in many other studies [22]. The
significant decrease in blood pressure is likely a combined
result of improvement of physical fitness and decrease in
body weight [23]. The beneficial metabolic effects of weight
loss are likely not to be only mechanical, as has beenpreviously proposed, but may involve a reduction of
cytokines produced in adipose tissue that influence vascular
reactivity [24].
A pronounced decrease in plasma hsCRP concentrations
was observed. Decreases in hsCRP concentrations after
weight reduction have been documented in 4 other recently
published interventional studies [9,11-13]. IL-6 is a medi-
ator of CRP production, which is produced by monocytes
and macrophages in response to low-grade infection or any
other inflammatory stimuli. It has been suggested that
elevated nonimmediate production of hsCRP is mediated by
a regulatory pathway similar to the one of immediate
reaction, via IL-6. Because up to one third of circulating
IL-6 is produced by adipose tissue [25], IL-6 could be an
important mediator linking obesity and proinflammatory
status as assessed by elevated hsCRP levels. Proinflamma-
tory status associated with obesity may be mediated by
adipocyte cytokine production. It is unlikely that the young
and relatively healthy subjects included in the present study
had advanced atherosclerotic lesions containing activated
macrophages; it is probable that the main source of
measured IL-6 is adipose tissue.
No correlation between the changes in hsCRP and IL-6
concentrations was documented in our study. Although a
highly significant (30%) decrease in hsCRP concentrations
was observed, IL-6 concentrations were not significantly
altered. Similar results were found in the study by Laimer
et al [11]. In the recent study by Klein et al [26], no change
in hsCRP concentration was observed after liposuction. In
contrast, in 2 other studies, IL-6 concentration decreased
after weight reduction, and the decrease was correlated with
change in hsCRP concentrations. The reason for this
discrepancy may be in the design of the studies: different
periods of follow-up and variations in the design of the
weight loss protocol. In the study of Kopp et al [13], weight
reduction was achieved solely by lowering of energy intake,
and in the study of Esposito et al [12], the physical activity
component was modest compared with intensive controlled
physical training in the presented study. In our study,
2 different mechanisms were included in the intervention:
lowering of energy intake and increase in intensive physical
activity. Joining of these 2 components may have had an
additive effect on the improvement of metabolic parameters;
however, it is not possible to determine their individual
contributions in a study with combined intervention.
According to the report by Keller et al [27], IL-6
concentrations increase with physical activity. Thus, it is
possible that the increase in physical activity also influenced
IL-6 production in the present study.
Adiponectin is a large-molecular-weight adipocyte-
derived hormone. Low circulating levels of adiponectin
are associated with components of the metabolic syndrome,
including visceral obesity, elevated triacylglycerols, low
HDL, and insulin resistance [28]. Reduced circulating
adiponectin levels in obese subjects have been hypothesized
to be involved in the pathogenesis of atherosclerosis and
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direct protective anti-inflammatory effects on vascular
endothelium [30] and protects against atherosclerosis in
apolipoprotein E–deficient mice [31]. Data from large cross-
sectional studies demonstrate that adiponectin levels are
positively related to plasma HDL-C and insulin sensitivity,
and negatively correlated with triacylglycerols and CRP,
independent of sex or body adiposity [32,33].
In this study, plasma adiponectin levels did not increase
after weight loss induced by the lifestyle intervention.
Circulating adiponectin levels do not increase with modest
weight loss induced by short-term energy-restricted diet [34]
or liposuction [26]. Plasma adiponectin does increase after
marked weight loss such as that induced by gastric bypass
surgery [35], and the increase in adiponectin is associated
with improved insulin sensitivity after weight loss [35]. It
has been hypothesized that adiponectin production is
regulated by adipocyte size and insulin sensitivity and that
a substantial reduction of adipocyte size is required to
increase adiponectin production and circulating adiponectin
concentrations [28]. Therefore, the modest degree of weight
reduction in the present study was insufficient to augment
adiponectin production. The changes in adiponectin are
unlikely to be involved in the observed anti-inflammatory
response or improved insulin sensitivity. However, because
available assays for adiponectin only measure the total level
of the circulating protein, changes in the distribution of
adiponectin complexes from low- to high-molecular-weight
multimers cannot be ruled out. An increased ratio of the
high-to low-molecular-weight forms of adiponectin has
been implicated as an important contributor to hepatic
insulin sensitivity [36].
An alternative pathway regulating inflammation and
plasma hsCRP concentrations, other than IL-6 or adiponec-
tin, is likely to exist. Results from other studies suggest that
the relationship between hsCRP concentration and inflam-
matory cytokines is not straightforward. For example, in the
study by Silvestri et al [37], plasma hsCRP concentration
increased after the introduction of hormonal replacement
therapy, but all other inflammatory parameters measured
(eg, IL-6, adhesion molecules) were decreased. In the
present study, by linear regression analysis, the change in
hsCRP concentration was best described by the changes in
only 3 other variables: triacylglycerol and FFA concen-
trations, and waist circumference. Elevated triacylglycerol
concentration and abdominal obesity, along with insulin
resistance and hypertension, are involved in metabolic
syndrome. It has been suggested that subclinical inflamma-
tion is an additional component of the metabolic syndrome,
linking obesity with insulin resistance and atherosclerosis
[7]. This hypothesis is supported by the observation that
baseline hsCRP concentrations are positively related to
BMI, waist circumference, and visceral fat mass.
High-sensitivity CRP baseline * waist difference param-
eter in the linear regression analysis suggests that interin-
dividual variability has an important influence on theresults. Accordingly, the present observation indicates that
different volunteers with the same decrease in waist
circumference would have different decrease in hsCRP
concentration. The impact is much more pronounced in
subjects with higher initial values of CRP. The underlying
basis for this observation is likely to be genetic: genetic
polymorphisms in regulatory loci may result in a suscepti-
bility to higher immune reactivity and elevated expression
of immediate-phase related proteins, even under basal
conditions (eg, in the absence of immediate proinflamma-
tory stimuli).5. Conclusion
Circulating concentrations of hsCRP decreased in young
obese women after weight reduction achieved by an
intervention designed to lower energy intake and increase
physical activity. The changes in hsCRP concentration did
not appear to be mediated by changes in IL-6 or adiponectin
concentrations. The association between the changes
in hsCRP and the changes in plasma triacylglycerols and
FFA links subclinical inflammation with dysregulation of
lipid metabolism in metabolic syndrome (mostly character-
ized by hypertriacyglycerolemia), thus suggesting that
subclinical inflammation may be an integral part of
metabolic syndrome.Acknowledgment
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